Cross-resistance of Mycobacterium tuberculosis isolates among streptomycin, kanamycin and amikacin.
Seventy-four streptomycin (SM)-resistant M. tuberculosis clinical isolates were subjected to cross-resistance drug testing against two major aminoglycosides, kanamycin (KM) and amikacin (AMK). Among them, 15 clinical isolates (20.3%) were resistant to both KM and AMK. Fifteen (80%) of 19 KM-resistant isolates were AMK-resistant. Fifteen SM, KM, and AMK resistant isolates harbored rrs mutation, but only two had rrs and rpsL double mutations. Low-level SM resistance was associated with rpsL mutation, whereas high-level SM resistance was linked to rrs mutation.
Sugawara
I
I
Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3-1-24 Matsuyama, Kiyose, Tokyo 204-0022, Japan. sugawara@jata.or.jp
Zhang
J
J
Li
C
C
D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007612:Kanamycin / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000502:physiology; D013307:Streptomycin / Q000494:pharmacology / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000382:microbiology
D000900:Anti-Bacterial Agents; D007612:Kanamycin; D000583:Amikacin; D013307:Streptomycin